These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21522147)

  • 1. Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.
    Waddell T; Kotsori A; Constantinidou A; Yousaf N; Ashley S; Parton M; Allen M; Starling N; Papadopoulos P; O'Brien M; Smith I; Johnston S
    Br J Cancer; 2011 May; 104(11):1675-9. PubMed ID: 21522147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
    Esposito A; Munzone E; Bagnardi V; Adamoli L; Sciandivasci A; Cullurà D; Goldhirsch A; Nolè F
    Anticancer Drugs; 2012 Nov; 23(10):1089-98. PubMed ID: 22760210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
    García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
    Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
    Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
    Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
    J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
    Fabi A; Metro G; Ferretti G; Giannarelli D; Di Cosimo S; Papaldo P; Mottolese M; Carlini P; Felici A; Russillo M; Cognetti F
    Breast; 2008 Oct; 17(5):499-505. PubMed ID: 18450443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.
    Bartsch R; De Vries C; Pluschnig U; Dubsky P; Bago-Horvath Z; Gampenrieder SP; Rudas M; Mader RM; Rottenfusser A; Wiltschke C; Gnant M; Zielinski CC; Steger GG
    BMC Cancer; 2009 Oct; 9():367. PubMed ID: 19835621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hayashi M; Okumura Y; Osako T; Toyozumi Y; Arima N; Iwase H; Nishimura R
    Int J Clin Oncol; 2011 Dec; 16(6):694-700. PubMed ID: 21556795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
    Montemurro F; Donadio M; Clavarezza M; Redana S; Jacomuzzi ME; Valabrega G; Danese S; Vietti-Ramus G; Durando A; Venturini M; Aglietta M
    Oncologist; 2006 Apr; 11(4):318-24. PubMed ID: 16614227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
    Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
    Adamo V; Franchina T; Adamo B; Ferraro G; Rossello R; Maugeri Saccà M; Scibilia C; Valerio MR; Russo A
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi11-5. PubMed ID: 17591801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
    von Minckwitz G; du Bois A; Schmidt M; Maass N; Cufer T; de Jongh FE; Maartense E; Zielinski C; Kaufmann M; Bauer W; Baumann KH; Clemens MR; Duerr R; Uleer C; Andersson M; Stein RC; Nekljudova V; Loibl S
    J Clin Oncol; 2009 Apr; 27(12):1999-2006. PubMed ID: 19289619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
    Miller KD; Diéras V; Harbeck N; Andre F; Mahtani RL; Gianni L; Albain KS; Crivellari D; Fang L; Michelson G; de Haas SL; Burris HA
    J Clin Oncol; 2014 May; 32(14):1437-44. PubMed ID: 24733796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.